{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:27:56Z","timestamp":1793392076856,"version":"4.5.0"},"reference-count":176,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Committee of Science of the Ministry of Science and Higher Education of the Republic of Kazakhstan","award":["BR24992950"],"award-info":[{"award-number":["BR24992950"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Pleural malignancies represent a clinically devastating group of oncological disorders, most commonly arising from metastatic disease, with lung and breast cancers being the most frequent primary sites. Malignant pleural mesothelioma is a primary malignancy of the pleura and occurs less often than metastatic pleural disease. Pleural malignancies often present with malignant pleural effusion, which typically indicates advanced-stage disease and is associated with poor overall prognosis. Treatment of pleural malignancies includes both palliative and definitive approaches. Palliative interventions primarily aim to relieve symptoms and improve quality of life. Definitive treatments include systemic chemotherapy, targeted therapy, and immunotherapy, depending on the type and molecular profile of the underlying tumor. In mesothelioma, platinum-based chemotherapy in combination with pemetrexed remains the cornerstone of treatment, while the combination of nivolumab and ipilimumab is recommended as first-line therapy for unresectable disease. For metastatic disease, systemic therapy is typically tailored to the primary tumor\u2019s characteristics. Intrapleural administration of chemotherapeutic agents is one of the therapeutic strategies and hyperthermic intrathoracic chemotherapy and pressurized intrathoracic aerosol chemotherapy are the most recent innovations that are under active investigation. This review provides an up-to-date synthesis of systemic chemotherapy strategies for pleural malignancies, their integration with targeted and immune-based therapies, and recent advances in intrapleural chemotherapy modalities. It also explores existing knowledge gaps and outlines directions for future research and potential changes in clinical practice.<\/jats:p>","DOI":"10.3390\/cancers17132143","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T03:39:59Z","timestamp":1750909199000},"page":"2143","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1324-7806","authenticated-orcid":false,"given":"Yuliya","family":"Semenova","sequence":"first","affiliation":[{"name":"Department of Surgery, School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhandos","family":"Burkitbayev","sequence":"additional","affiliation":[{"name":"Chairman of the board, National Research Oncology Center, Astana 020000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurtas","family":"Kalibekov","sequence":"additional","affiliation":[{"name":"Department of Multidisciplinary Surgery, National Research Oncology Center, Astana 020000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandr","family":"Digay","sequence":"additional","affiliation":[{"name":"Department of Multidisciplinary Surgery, National Research Oncology Center, Astana 020000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakhyt","family":"Zhaxybayev","sequence":"additional","affiliation":[{"name":"Department of Multidisciplinary Surgery, National Research Oncology Center, Astana 020000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oxana","family":"Shatkovskaya","sequence":"additional","affiliation":[{"name":"Vice-Chairman of the board for Strategic Development, Scientific and Educational Activities, National Research Oncology Center, Astana 020000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6975-7541","authenticated-orcid":false,"given":"Saule","family":"Khamzina","sequence":"additional","affiliation":[{"name":"Department of Multidisciplinary Surgery, National Research Oncology Center, Astana 020000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinara","family":"Zharlyganova","sequence":"additional","affiliation":[{"name":"Department of Scientific Management, National Research Oncology Center, Astana 020000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuldyz","family":"Kuanysh","sequence":"additional","affiliation":[{"name":"Department of Scientific Management, National Research Oncology Center, Astana 020000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almira","family":"Manatova","sequence":"additional","affiliation":[{"name":"Department of Scientific Management, National Research Oncology Center, Astana 020000, Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Corrin, B., and Nicholson, A.G. (2011). Pleura and Chest Wall. Pathology of the Lungs, Churchill Livingstone. [3rd ed.].","DOI":"10.1016\/B978-0-7020-3369-8.00013-6"},{"key":"ref_2","first-page":"e20210129","article-title":"Malignant pleural mesothelioma: An update","volume":"47","author":"Hajj","year":"2021","journal-title":"J. Bras. Pneumol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.amjmed.2022.04.017","article-title":"Malignant pleural effusion: Presentation, diagnosis, and management","volume":"135","author":"Gayen","year":"2022","journal-title":"Am. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"230145","DOI":"10.1183\/20734735.0145-2023","article-title":"Malignant pleural disease","volume":"19","author":"Piggott","year":"2023","journal-title":"Breathe"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ccm.2021.08.004","article-title":"Malignant Pleural Effusions","volume":"42","author":"Kapp","year":"2021","journal-title":"Clin. Chest Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1183\/16000617.0019-2016","article-title":"Malignant Pleural Effusion: From Bench to Bedside","volume":"25","author":"Psallidas","year":"2016","journal-title":"Eur. Respir. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"A3650","DOI":"10.1016\/j.chest.2024.06.2184","article-title":"Incremental Health Care Utilization and Cost of Malignant Pleural Effusion","volume":"166","author":"Fitzpatrick","year":"2024","journal-title":"Chest"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zamboni, M.M., da Silva, C.T., Baretta, R., Cunha, E.T., and Cardoso, G.P. (2015). Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulm. Med., 15.","DOI":"10.1186\/s12890-015-0025-z"},{"key":"ref_9","unstructured":"Psallidas, I. (2015). Malignant Pleural Effusion: Investigating Novel Diagnostic and Therapeutic Approaches. [Ph.D. Thesis, University of Oxford]. Available online: https:\/\/ora.ox.ac.uk\/objects\/uuid:7afb0213-dfc9-48d3-9e76-61b082965a58."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"ii29","DOI":"10.1136\/thx.58.suppl_2.ii29","article-title":"Management of malignant pleural effusions","volume":"58","author":"Antunes","year":"2003","journal-title":"Thorax"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: Scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_12","first-page":"CD010529","article-title":"Palliative interventions for malignant pleural effusions: A network meta-analysis","volume":"5","author":"Clive","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.disamonth.2012.11.002","article-title":"Pleural Effusions","volume":"59","author":"Porcel","year":"2013","journal-title":"Dis. Mon."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1164\/ajrccm.162.5.ats8-00","article-title":"Management of Malignant Pleural Effusions","volume":"162","author":"Baumann","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_15","first-page":"6884","article-title":"Hyperthermic intrathoracic chemotherapy (HITOC) for malignant pleural diseases: A systematic review","volume":"13","author":"Hsieh","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12931-024-02684-7","article-title":"Malignant pleural effusion: Current understanding and therapeutic approach","volume":"25","author":"Gonnelli","year":"2024","journal-title":"Respir. Res."},{"key":"ref_17","unstructured":"Sharma, S., and Boster, J. (2024). Malignant Pleural Effusion. StatPearls, StatPearls Publishing."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"00050","DOI":"10.1183\/23120541.00050-2024","article-title":"Clinical overview of the physiology and pathophysiology of pleural fluid movement: A narrative review","volume":"10","author":"Ferreiro","year":"2024","journal-title":"ERJ Open Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1183\/09031936.97.10071566","article-title":"Urokinase-type plasminogen activator in carcinomatous pleural fluid","volume":"10","author":"Ishikawa","year":"1997","journal-title":"Eur. Respir. J."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Choi, H., Ko, Y., and Lee, C.Y. (2020). Pro-cathepsin D as a diagnostic marker in differentiating malignant from benign pleural effusion: A retrospective cohort study. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07327-w"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Granberg, D., Juhlin, C.C., Falhammar, H., and Hedayati, E. (2023). Lung carcinoids: A comprehensive review for clinicians. Cancers, 15.","DOI":"10.3390\/cancers15225440"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21037\/amj.2020.02.04","article-title":"Malignant pleural effusion and mesothelioma","volume":"5","author":"Subotic","year":"2020","journal-title":"AME Med. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1038\/s41388-023-02844-x","article-title":"Biophysics in tumor growth and progression: From single mechano-sensitive molecules to mechanomedicine","volume":"42","author":"Xin","year":"2023","journal-title":"Oncogene"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/JTO.0000000000000122","article-title":"The challenge of malignant pleural mesothelioma: New directions","volume":"9","author":"Rusch","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO Classification of Tumors of the Pleura: Advances since the 2015 classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"543","DOI":"10.21037\/tlcr.2018.07.05","article-title":"The eighth TNM classification for malignant pleural mesothelioma","volume":"7","author":"Berzenji","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_27","unstructured":"Cheng, J., Sharma, R., and Campos, A. (2025, April 22). Cotswolds-Modified Ann Arbor Classification. Radiopaedia.org. Available online: https:\/\/radiopaedia.org\/articles\/cotswolds-modified-ann-arbor-classification-2?lang=us."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"106802","DOI":"10.1016\/j.rmed.2022.106802","article-title":"Update on the diagnosis and management of malignant pleural effusions","volume":"196","author":"Bashour","year":"2022","journal-title":"Respir. Med."},{"key":"ref_29","unstructured":"Medscape (2025, April 25). Pleural Effusion Imaging. Available online: https:\/\/emedicine.medscape.com\/article\/355524-overview?form=fpf."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Shehata, S.M., Almalki, Y.E., Basha, M.A.A., Hendy, R.M., Mahmoud, E.M., Abd Elhamed, M.E., Alduraibi, S.K., Aboualkheir, M., Almushayti, Z.A., and Alduraibi, A.K. (2024). Comparative evaluation of chest ultrasonography and computed tomography as predictors of malignant pleural effusion: A prospective study. Diagnostics, 14.","DOI":"10.3390\/diagnostics14101041"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.3390\/curroncol31090368","article-title":"Diagnosis of pleural mesothelioma: Is everything solved at the present time?","volume":"31","author":"Roca","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.3390\/curroncol31110507","article-title":"Malignant Pleural Effusion: Diagnosis and Treatment\u2014Up-to-Date Perspective","volume":"31","author":"Orlandi","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/ejcts\/ezy258","article-title":"ERS\/EACTS Statement on the Management of Malignant Pleural Effusions","volume":"55","author":"Bibby","year":"2019","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1513\/AnnalsATS.201809-620CME","article-title":"Summary for Clinicians: Clinical Practice Guideline for Management of Malignant Pleural Effusions","volume":"16","author":"Reddy","year":"2019","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_35","first-page":"e20240115","article-title":"Talc Slurry versus Thoracoscopic Talc Insufflation for Malignant Pleural Effusion: A Systematic Review and Meta-Analysis","volume":"50","author":"Rodrigues","year":"2024","journal-title":"J. Bras. Pneumol."},{"key":"ref_36","first-page":"CD010529","article-title":"Interventions for the Management of Malignant Pleural Effusions: A Network Meta-Analysis","volume":"4","author":"Dipper","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-Pleural Pneumonectomy versus No Extra-Pleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma: Clinical Outcomes of the Mesothelioma and Radical Surgery (MARS) Randomised Feasibility Study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4103\/0973-1075.84529","article-title":"An Update in the Management of Malignant Pleural Effusion","volume":"17","author":"Muduly","year":"2011","journal-title":"Indian J. Palliat. Care"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"295","DOI":"10.21037\/tlcr.2017.06.01","article-title":"Novel Systemic Therapy against Malignant Pleural Mesothelioma","volume":"6","author":"Mancuso","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.22.02542","article-title":"Phase III Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma","volume":"41","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized Phase III Study of Cisplatin with or without Raltitrexed in Patients with Malignant Pleural Mesothelioma: An Intergroup Study","volume":"23","author":"Gaafar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdm501","article-title":"Phase II Study of Pemetrexed in Combination with Carboplatin in Patients with Malignant Pleural Mesothelioma (MPM)","volume":"19","author":"Castagneto","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bjc.6604442","article-title":"Pemetrexed plus Carboplatin in Elderly Patients with Malignant Pleural Mesothelioma: Combined Analysis of Two Phase II Trials","volume":"99","author":"Ceresoli","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3816\/CLC.2010.n.005","article-title":"Carboplatin plus Pemetrexed as First-Line Treatment of Patients with Malignant Pleural Mesothelioma: A Phase II Study","volume":"11","author":"Katirtzoglou","year":"2010","journal-title":"Clin. Lung Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus Cisplatin or Pemetrexed plus Carboplatin for Chemona\u00efve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program","volume":"3","author":"Santoro","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2302114","DOI":"10.1183\/13993003.02114-2023","article-title":"A Randomised Phase II Study of Extended Pleurectomy\/Decortication Preceded or Followed by Chemotherapy in Patients with Early-Stage Pleural Mesothelioma: EORTC 1205","volume":"63","author":"Raskin","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kotecha, R., Tonse, R., Rubens, M., Appel, H., Albrecht, F., Kaywin, P., Alley, E.W., Tom, M.C., and Mehta, M.P. (2021). Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy. Cancers, 13.","DOI":"10.3390\/cancers13092186"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.1999.17.1.25","article-title":"Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II Study","volume":"17","author":"Byrne","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.lungcan.2008.09.008","article-title":"Outcomes with First-Line Platinum-Based Combination Chemotherapy for Malignant Pleural Mesothelioma: A Review of Practice in British Columbia","volume":"64","author":"Lee","year":"2009","journal-title":"Lung Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1200\/JCO.2007.15.2868","article-title":"Phase II Trial of Pemetrexed and Gemcitabine in Chemotherapy-Naive Malignant Pleural Mesothelioma","volume":"26","author":"Simon","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2000.18.23.3912","article-title":"Phase II Study of Vinorelbine in Patients with Malignant Pleural Mesothelioma","volume":"18","author":"Steele","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.lungcan.2004.08.005","article-title":"Phase II Trial of Vinorelbine and Oxaliplatin as First-Line Therapy in Malignant Pleural Mesothelioma","volume":"47","author":"Fennell","year":"2005","journal-title":"Lung Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"101432","DOI":"10.1016\/j.eclinm.2022.101432","article-title":"Active Symptom Control with or without Oral Vinorelbine in Patients with Relapsed Malignant Pleural Mesothelioma (VIM): A Randomised, Phase 2 Trial","volume":"48","author":"Fennell","year":"2022","journal-title":"eClinicalMedicine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1200\/JCO.1993.11.8.1559","article-title":"Randomized Phase II Trial of Cisplatin with Mitomycin or Doxorubicin for Malignant Mesothelioma by the Cancer and Leukemia Group B","volume":"11","author":"Chahinian","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"ref_56","first-page":"1431","article-title":"Randomized Trial of Doxorubicin versus Cyclophosphamide in Diffuse Malignant Pleural Mesothelioma","volume":"69","author":"Bach","year":"1985","journal-title":"Cancer Treat. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and Gemcitabine as Second- or Third-Line Therapy for Malignant Pleural Mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000510691","article-title":"Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma Following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study","volume":"99","author":"Koda","year":"2021","journal-title":"Oncology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.annonc.2019.12.009","article-title":"Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: An international, multi-centre, single-arm, phase II trial (SAKK 17\/16)","volume":"31","author":"Metaxas","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12254-018-0408-y","article-title":"Systemic treatment of advanced non-small cell lung cancer: Controversies and perspectives","volume":"11","author":"Tiefenbacher","year":"2018","journal-title":"Memo"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1023\/A:1008336931378","article-title":"Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: A multicenter phase II trial","volume":"11","author":"Manegold","year":"2000","journal-title":"Ann. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.2012.48.1911","article-title":"Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2","volume":"31","author":"Zukin","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"NSCLC Meta-Analyses Collaborative Group (2008). Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J. Clin. Oncol., 26, 4617\u20134625.","DOI":"10.1200\/JCO.2008.17.7162"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.3747\/co.25.3792","article-title":"Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: An evidence-based overview","volume":"25","author":"Daaboul","year":"2018","journal-title":"Curr. Oncol."},{"key":"ref_68","unstructured":"Columbia University Irving Medical Center (2025, May 03). Small Cell Lung Cancer Treatment (PDQ\u00ae): Treatment\u2014Health Professional Information [NCI]. Available online: https:\/\/www.columbiadoctors.org\/health-library\/nci-pdq-cancer\/small-cell-lung-cancer-treatment-pdq-treatment-health-professional-information-nci\/?utm_source=chatgpt.com."},{"key":"ref_69","unstructured":"Medscape (2025, May 03). Small Cell Lung Cancer (SCLC) Treatment & Management. Available online: https:\/\/emedicine.medscape.com\/article\/280104-treatment?utm_source=chatgpt.com&form=fpf."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1634\/theoncologist.2017-0204","article-title":"Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer","volume":"22","author":"Stinchcombe","year":"2017","journal-title":"Oncologist"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/oxfordjournals.annonc.a058931","article-title":"Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study","volume":"5","author":"Skarlos","year":"1994","journal-title":"Ann. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","article-title":"Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data","volume":"30","author":"Rossi","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Jiang, S., Huang, L., Zhen, H., Jin, P., Wang, J., and Hu, Z. (2021). Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: A pooled analysis. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-09034-6"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMoa003034","article-title":"Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer","volume":"346","author":"Noda","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2005.04.8595","article-title":"Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer","volume":"24","author":"Hanna","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.2008.20.1061","article-title":"Phase III trial of irinotecan\/cisplatin compared with etoposide\/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124","volume":"27","author":"Lara","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.ejca.2007.07.029","article-title":"Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer","volume":"43","author":"Groen","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.2013.53.5153","article-title":"Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509","volume":"32","author":"Satouchi","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/annonc\/mdn781","article-title":"Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)","volume":"20","author":"Katsumata","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e803","DOI":"10.1097\/MD.0000000000000803","article-title":"Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: A meta-analysis of randomized trials","volume":"94","author":"Zheng","year":"2015","journal-title":"Medicine"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Bria, E., Nistic\u00f2, C., Cuppone, F., Giannarelli, D., and Terzoli, E. (2004). Impact of taxanes in association with anthracyclines in 1st line chemotherapy for metastatic breast cancer (MBC): Comprehensive review of 2805 patients in 7 phase III trials. J. Clin. Oncol., 22.","DOI":"10.1200\/jco.2004.22.90140.659"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1610383","DOI":"10.3389\/pore.2022.1610383","article-title":"Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer","volume":"28","author":"Rubovszky","year":"2022","journal-title":"Pathol. Oncol. Res."},{"key":"ref_83","first-page":"549","article-title":"Gemcitabine in combination with vinorelbine for heavily pretreated advanced breast cancer","volume":"26","author":"Gennatas","year":"2006","journal-title":"Anticancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.breast.2021.03.002","article-title":"Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience","volume":"57","author":"Franzoi","year":"2021","journal-title":"Breast"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Harter","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ygyno.2006.12.018","article-title":"Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: A phase II trial","volume":"105","author":"Kushner","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"27","DOI":"10.21037\/amj-2019-mpe-07","article-title":"Pleural carcinosis caused by extrathoracic malignancies","volume":"6","author":"Migliore","year":"2021","journal-title":"AME Med. J."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Semenova, Y., Kerimkulov, A., Uskenbayev, T., Zharlyganova, D., Shatkovskaya, O., Sarina, T., Manatova, A., Yessenbayeva, G., and Adylkhanov, T. (2025). Chemotherapy Options for Locally Advanced Gastric Cancer: A Review. Cancers, 17.","DOI":"10.3390\/cancers17050809"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"820","DOI":"10.4251\/wjgo.v14.i4.820","article-title":"Management of Single Pulmonary Metastases from Colorectal Cancer: State of the Art","volume":"14","author":"Chiappetta","year":"2022","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/sj.bjc.6605347","article-title":"A Phase-II Trial of Dose-Dense Chemotherapy in Patients with Disseminated Thymoma: Report of a Japan Clinical Oncology Group Trial (JCOG 9605)","volume":"101","author":"Kunitoh","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"775","DOI":"10.6061\/clinics\/2015(12)03","article-title":"Chemotherapy and Prognosis in Advanced Thymic Carcinoma Patients","volume":"70","author":"Song","year":"2015","journal-title":"Clinics"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3324\/haematol.2014.111203","article-title":"Prognostic Significance of Pleural or Pericardial Effusion and the Implication of Optimal Treatment in Primary Mediastinal Large B-Cell Lymphoma: A Multicenter Retrospective Study in Japan","volume":"99","author":"Aoki","year":"2014","journal-title":"Haematologica"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for Newly Diagnosed Pleural Mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1200\/JCO.19.00269","article-title":"Phase II Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemotherapy-Na\u00efve Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)","volume":"37","author":"Tsao","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in Combination with Pemetrexed and Cisplatin for Chemotherapy-Naive Patients with Advanced Malignant Pleural Mesothelioma (LUME-Meso): A Double-Blind, Randomised, Placebo-Controlled Phase 3 Trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jtho.2016.01.014","article-title":"A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes","volume":"11","author":"Buikhuisen","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without Ramucirumab as Second-Line Treatment for Malignant Pleural Mesothelioma (RAMES): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1200\/JCO-24-02425","article-title":"Treatment of Pleural Mesothelioma: ASCO Guideline Update","volume":"43","author":"Kindler","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.lungcan.2011.11.014","article-title":"Vatalanib in Malignant Mesothelioma: A Phase II Trial by the Cancer and Leukemia Group B (CALGB 30107)","volume":"76","author":"Jahan","year":"2012","journal-title":"Lung Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cllc.2013.12.008","article-title":"Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma","volume":"15","author":"Tsao","year":"2014","journal-title":"Clin. Lung Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2020.12.028","article-title":"Expression of EGFR and Conformational Forms of EGFR in Malignant Pleural Mesothelioma and Its Impact on Survival","volume":"153","author":"Chia","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","article-title":"Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B","volume":"11","author":"Govindan","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","article-title":"Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study","volume":"25","author":"Garland","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3892\/ijo.2012.1607","article-title":"Therapeutic Antitumor Efficacy of Anti-Epidermal Growth Factor Receptor Antibody, Cetuximab, against Malignant Pleural Mesothelioma","volume":"41","author":"Kurai","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e20030","DOI":"10.1200\/JCO.2017.35.15_suppl.e20030","article-title":"Cetuximab plus Platinum-Based Chemotherapy in Patients with Malignant Pleural Mesothelioma: A Single Arm Phase II Trial","volume":"35","author":"Vermaelen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","article-title":"SWOG S0722: Phase II Study of MTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)","volume":"10","author":"Ou","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s10637-021-01086-6","article-title":"Phase 1 Cohort Expansion Study of LY3023414, a Dual PI3K\/mTOR Inhibitor, in Patients with Advanced Mesothelioma","volume":"39","author":"Zauderer","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10637-019-00783-7","article-title":"A Phase Ib Study of GSK3052230, an FGF Ligand Trap in Combination with Pemetrexed and Cisplatin in Patients with Malignant Pleural Mesothelioma","volume":"38","author":"Levchenko","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND\u2014A Double-Blind, Randomized, Phase II Study","volume":"37","author":"Fennell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Borea, F., Franczak, M.A., Garcia, M., Perrino, M., Cordua, N., Smolenski, R.T., Peters, G.J., Dziadziuszko, R., Santoro, A., and Zucali, P.A. (2023). Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119165"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/S2213-2600(22)00301-0","article-title":"NICE Guidance on Nivolumab plus Ipilimumab for Untreated, Unresectable Malignant Pleural Mesothelioma","volume":"10","author":"Adler","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus Chemotherapy versus Chemotherapy in Untreated Advanced Pleural Mesothelioma in Canada, Italy, and France: A Phase 3, Open-Label, Randomised Controlled Trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Messori, A., Trippoli, S., Piragine, E., Veneziano, S., and Calderone, V. (2025). A Meta-Analysis of First-Line Treatments for Unresectable Pleural Mesothelioma: Indirect Comparisons from Reconstructed Individual Patient Data of Six Randomized Controlled Trials. Cancers, 17.","DOI":"10.3390\/cancers17030503"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: Survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): A multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1078-0432.CCR-22-2566","article-title":"A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma","volume":"29","author":"Lee","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S2213-2600(21)00043-6","article-title":"Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: A follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study","volume":"9","author":"Rossi","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s12032-013-0676-7","article-title":"Phase 2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion","volume":"30","author":"Tamiya","year":"2013","journal-title":"Med. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.lungcan.2016.07.003","article-title":"A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A","volume":"99","author":"Usui","year":"2016","journal-title":"Lung Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/1759-7714.13238","article-title":"A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer","volume":"11","author":"Nie","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"113318","DOI":"10.18632\/oncotarget.22966","article-title":"Evaluation of efficacy and safety for bevacizumab in treating malignant pleural effusions caused by lung cancer through intrapleural injection","volume":"8","author":"Zongwen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.21037\/tlcr-24-508","article-title":"Phase II study of ramucirumab and docetaxel for previously platinum-treated patients with non-small cell lung cancer and malignant pleural effusion (PLEURAM study)","volume":"13","author":"Takemoto","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cllc.2014.04.002","article-title":"Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion","volume":"15","author":"Massarelli","year":"2014","journal-title":"Clin. Lung Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11523-014-0306-0","article-title":"A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion","volume":"9","author":"Mulder","year":"2014","journal-title":"Target Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3892\/ijo.2021.5174","article-title":"Novel therapies for malignant pleural effusion: Anti angiogenic therapy and immunotherapy (Review)","volume":"58","author":"He","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Wei, Q., Deng, T., Wu, J., Zeng, H., Qi, C., Tan, S., Zhang, Y., Huang, Q., Pu, X., and Xu, W. (2024). Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: A retrospective multicenter study. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12173-1"},{"key":"ref_131","first-page":"100355","article-title":"Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study","volume":"3","author":"Kawachi","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_132","first-page":"1103","article-title":"Multicenter phase 2 study of intrapleural nivolumab in patients with metastatic non-small cell lung cancer and pleural effusion","volume":"13","author":"Tsimafeyeu","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"S349","DOI":"10.1016\/j.jtho.2021.01.551","article-title":"P16.05 Exploratory Study of Sintilimab Intrapleural Therapy for NSCLC-Mediated Malignant Pleural Effusion","volume":"16","author":"Lv","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.lungcan.2020.10.007","article-title":"Oncolytic herpesvirus therapy for mesothelioma\u2014A phase I\/IIa trial of intrapleural administration of HSV1716","volume":"150","author":"Danson","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1200\/jco.2015.33.15_suppl.7559","article-title":"Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion","volume":"33","author":"Krug","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/cncr.20843","article-title":"A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma","volume":"103","author":"Chang","year":"2005","journal-title":"Cancer"},{"key":"ref_137","first-page":"4587","article-title":"Better Clinical Efficiency of TILs for Malignant Pleural Effusion and Ascites than Cisplatin Through Intrapleural and Intraperitoneal Infusion","volume":"37","author":"Chu","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"955","DOI":"10.21037\/atm-20-5444","article-title":"Hyperthermic intrathoracic chemotherapy (HITHOC): Narrative review of the current literature, recommendations and future studies","volume":"9","author":"Markowiak","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/ejcts\/ezu217","article-title":"Assessment of cisplatin concentration and depth of penetration in human lung tissue after hyperthermic exposure","volume":"47","author":"Ried","year":"2015","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e16769","DOI":"10.1016\/j.heliyon.2023.e16685","article-title":"Comparison of Video-Assisted Pleurectomy\/Decortication Surgery Plus Hyperthermic Intrathoracic Chemotherapy with VATS Talc Pleurodesis for the Treatment of Malignant Pleural Mesothelioma: A Pilot Study","volume":"9","author":"Migliore","year":"2023","journal-title":"Heliyon"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/1759-7714.14361","article-title":"Hyperthermic intrathoracic chemotherapy for the treatment of malignant pleural effusion caused by breast and ovarian cancer: A systematic literature review and pooled analysis","volume":"13","author":"Karampinis","year":"2022","journal-title":"Thorac. Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"J\u00e4rvinen, T., Paajanen, J., Ilonen, I., and R\u00e4s\u00e4nen, J. (2021). Hyperthermic Intrathoracic Chemoperfusion for Malignant Pleural Mesothelioma: Systematic Review and Meta-Analysis. Cancers, 13.","DOI":"10.3390\/cancers13143637"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e5532","DOI":"10.1097\/MD.0000000000005532","article-title":"Effect of Hyperthermic Intrathoracic Chemotherapy (HITHOC) on the Malignant Pleural Effusion: A Systematic Review and Meta-Analysis","volume":"96","author":"Zhou","year":"2017","journal-title":"Medicine"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/thoraxjnl-2021-218214","article-title":"Cytoreductive Surgery with Hyperthermic Intrathoracic Chemotherapy for Malignant Pleural Mesothelioma: A Systematic Review","volume":"78","author":"Dawson","year":"2023","journal-title":"Thorax"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.2005.04.6813","article-title":"Phase I to II Study of Pleurectomy\/Decortication and Intraoperative Intracavitary Hyperthermic Cisplatin Lavage for Mesothelioma","volume":"24","author":"Richards","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e041511","DOI":"10.1136\/bmjopen-2020-041511","article-title":"Protocol of a Retrospective, Multicentre Observational Study on Hyperthermic Intrathoracic Chemotherapy in Germany","volume":"10","author":"Markowiak","year":"2020","journal-title":"BMJ Open"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtcvs.2012.12.037","article-title":"Hyperthermic Intraoperative Pleural Cisplatin Chemotherapy Extends Interval to Recurrence and Survival among Low-Risk Patients with Malignant Pleural Mesothelioma Undergoing Surgical Macroscopic Complete Resection","volume":"145","author":"Sugarbaker","year":"2013","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.21037\/jtd.2019.04.93","article-title":"Pleurectomy\/Decortication and Hyperthermic Intrathoracic Chemoperfusion Using Cisplatin and Doxorubicin for Malignant Pleural Mesothelioma","volume":"11","author":"Klotz","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Ried, M., Kov\u00e1cs, J., Markowiak, T., M\u00fcller, K., Huppertz, G., Koller, M., Winter, H., Klotz, L.V., Hatz, R., and Zimmermann, J. (2021). Hyperthermic Intrathoracic Chemotherapy (HITOC) after Cytoreductive Surgery for Pleural Malignancies\u2014A Retrospective, Multicentre Study. Cancers, 13.","DOI":"10.3390\/cancers13184580"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-0039-1700883","article-title":"Surgical Cytoreduction and HITOC for Thymic Malignancies with Pleural Dissemination","volume":"69","author":"Markowiak","year":"2021","journal-title":"Thorac. Cardiovasc. Surg."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.jtcvs.2017.10.070","article-title":"Diaphragm and Lung-Preserving Surgery with Hyperthermic Chemotherapy for Malignant Pleural Mesothelioma: A 10-Year Experience","volume":"155","author":"Ambrogi","year":"2018","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/icvts\/ivaa019","article-title":"Surgical Treatment of Pleural Recurrence of Thymoma: Is Hyperthermic Intrathoracic Chemotherapy Worthwhile?","volume":"30","author":"Aprile","year":"2020","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jtho.2018.04.032","article-title":"A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma","volume":"13","author":"Burt","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1200\/jco.2008.26.15_suppl.2551","article-title":"A novel intra-thoracic hyperthermic schedule combining gemcitabine (Gem) and cisplatin (Pt) in patients with pleural mesothelioma: A pharmacokinetic analysis","volume":"26","author":"Milano","year":"2008","journal-title":"J Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s13193-018-0859-y","article-title":"Hyperthermic Intrathoracic Chemotherapy (HITHOC) for Pleural Malignancies\u2014Experience from Indian Centers","volume":"10","author":"Patel","year":"2019","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.gynor.2014.05.001","article-title":"Hyperthermic Intra-Thoracic Chemotherapy (HITeC) for the Management of Recurrent Ovarian Cancer Involving the Pleural Cavity","volume":"9","author":"Singh","year":"2014","journal-title":"Gynecol. Oncol. Case Rep."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jviscsurg.2025.01.002","article-title":"Abdominal and Concomitant Thoracic HIPEC, Named HITAC: Technique and Post-Operative Courses","volume":"162","author":"Djelil","year":"2025","journal-title":"J. Visc. Surg."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1515\/pp-2023-0048","article-title":"Review on Treatment of Pleural Metastasis and Malignant Pleural Effusion with Pressurized IntraThoracic Aerosol Chemotherapy (PITAC)","volume":"9","author":"Hansen","year":"2024","journal-title":"Pleura Peritoneum"},{"key":"ref_159","first-page":"1000127","article-title":"Safety and Efficacy of Pressurized Intraperitoneal\/Intrathoracic Aerosol Chemotherapy (PIPAC\/PITAC) in Patients with Peritoneal and\/or Pleural Carcinomatosis: A Preliminary Experience","volume":"2","author":"Kuchen","year":"2018","journal-title":"J. Med. Therap."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1515\/pp-2024-0014","article-title":"Implementation and Evaluation of Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) for the Treatment of Patients with Malignant Pleural Effusion: Study Protocol for the Danish Phase-I PITAC-OPC5 Study","volume":"9","author":"Hansen","year":"2024","journal-title":"Pleura Peritoneum"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"20200129","DOI":"10.1515\/pp-2020-0129","article-title":"Technique of Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) for Malignant Pleural Effusion","volume":"5","author":"Drevet","year":"2020","journal-title":"Pleura Peritoneum"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Giger-Pabst, U., Demtr\u00f6der, C., Falkenstein, T.A., Ouaissi, M., G\u00f6tze, T.O., Rezniczek, G.A., and Tempfer, C.B. (2018). Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the Treatment of Malignant Mesothelioma. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4363-0"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"100858","DOI":"10.1016\/j.ctarc.2024.100858","article-title":"Phase I Clinical Trial Testing the Dose Escalation and Expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration (PITHAC) for the Management of Pleural Carcinosis","volume":"42","author":"Chriqui","year":"2024","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jtho.2023.01.095","article-title":"NCD Global Health Research Group, Association of Pacific Rim Universities (APRU). Global Incidence, Risk Factors, and Temporal Trends of Mesothelioma: A Population-Based Study","volume":"18","author":"Huang","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a Blood and Effusion Biomarker for Pleural Mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chest.2016.12.004","article-title":"Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment","volume":"152","author":"Creaney","year":"2017","journal-title":"Chest"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/joim.13480","article-title":"Low-Dose Computed Tomography Lung Cancer Screening: Clinical Evidence and Implementation Research","volume":"292","author":"Lancaster","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_168","unstructured":"Tomlinson-Hansen, S.E., Budh, D.P., and Sapra, A. (2025). Breast Cancer Screening in the Average-Risk Patient. StatPearls, StatPearls Publishing."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.hoc.2022.02.001","article-title":"Screening for Colorectal Cancer","volume":"36","author":"Gupta","year":"2022","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_170","first-page":"1807","article-title":"Epidemiological Characteristics of Male Reproductive Cancers in the Republic of Kazakhstan: Ten-Year Trends","volume":"51","author":"Umurzakov","year":"2022","journal-title":"Iran J. Public Health"},{"key":"ref_171","first-page":"1807","article-title":"Incidence and Mortality of Cervical Cancer in the Republic of Kazakhstan: 2007\u20132016","volume":"49","author":"Shalgumbayeva","year":"2020","journal-title":"Iran J. Public Health"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Jain, M., Crites, M.K., Rich, P., and Bajantri, B. (2024). Malignant Pleural Mesothelioma: A Comprehensive Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13195837"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"430","DOI":"10.21037\/atm-21-6326","article-title":"Prognostic Role of Immune Microenvironment in Pleural Metastases from Breast and Lung Adenocarcinomas","volume":"10","author":"Karpathiou","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Wang, C.Q., Huang, X.R., He, M., Zheng, X.T., Jiang, H., Chen, Q., Fan, T.Y., Zhan, L., Ling, J., and Feng, J.H. (2021). Intrapleural Administration with Rh-Endostatin and Chemical Irritants in the Control of Malignant Pleural Effusion: A Systematic Review and Meta-Analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.649999"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejso.2004.08.014","article-title":"Improved Survival with VATS Pleurectomy\u2013Decortication in Advanced Malignant Mesothelioma","volume":"31","author":"Halstead","year":"2005","journal-title":"J. Surg. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S2213-2600(24)00253-4","article-title":"Further Insights into MARS 2","volume":"12","author":"Migliore","year":"2024","journal-title":"Lancet Respir. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2143\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:58:45Z","timestamp":1760032725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/13\/2143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":176,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["cancers17132143"],"URL":"https:\/\/doi.org\/10.3390\/cancers17132143","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]}}}